Key Insights

Highlights

Success Rate

83% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

3.4%

2 terminated out of 59 trials

Success Rate

83.3%

-3.2% vs benchmark

Late-Stage Pipeline

8%

5 trials in Phase 3/4

Results Transparency

20%

2 of 10 completed with results

Key Signals

2 with results83% success

Data Visualizations

Phase Distribution

50Total
Not Applicable (12)
P 1 (16)
P 2 (17)
P 4 (5)

Trial Status

Recruiting23
Unknown10
Completed10
Active Not Recruiting6
Not Yet Recruiting5
Withdrawn2

Trial Success Rate

83.3%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (59)

Showing 20 of 20 trials
NCT07551414Phase 2Not Yet Recruiting

Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI

NCT07398599Not ApplicableRecruitingPrimary

Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study

NCT04192981Phase 1Active Not Recruiting

GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases

NCT06282874Phase 4Active Not Recruiting

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

NCT07348965Not ApplicableRecruiting

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

NCT06984523Not ApplicableActive Not RecruitingPrimary

Study of Craniospinal Irradiation With Linac Based Volumetric Modulated Arc Therapy (VMAT) for Patients With Leptomeningeal Metastasis

NCT05805631Phase 2Recruiting

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

NCT06663306Phase 1Recruiting

Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

NCT06058988Phase 2Recruiting

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

NCT04588545Phase 1Recruiting

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

NCT06296745Phase 2RecruitingPrimary

Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

NCT06724926Phase 1Recruiting

Concurrent Azeliragon With Craniospinal Irradiation

NCT06230055Phase 4Recruiting

Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis

NCT07239102Completed

Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis

NCT05800275Phase 2RecruitingPrimary

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease

NCT05598853Phase 1Active Not RecruitingPrimary

Intrathecal Double Checkpoint Inhibition

NCT07199413Phase 1Not Yet Recruiting

Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases

NCT06304441Not ApplicableRecruitingPrimary

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

NCT06462222Phase 1Active Not RecruitingPrimary

Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors

NCT03974204Not ApplicableWithdrawn

Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.

Scroll to load more

Research Network

Activity Timeline